CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Thursday reported a loss of $196.5 million in its third quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.50.
The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.89 per share.
The biopharmaceutical company posted revenue of $143.9 million in the period, surpassing Street forecasts. Seven analysts surveyed by Zacks expected $131.5 million.
Sarepta Therapeutics shares have climbed 12% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $145.15, a rise of 55% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SRPT at https://www.zacks.com/ap/SRPT
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News